Pague Menos Posts Record 6.5% EBITDA Margin for Q2 2026, But Financial Costs and SSS Slowdown Temper Net Income Growth

Brazilian pharmacy chain Empreendimentos Pague Menos S.A. (PGMN3) achieved a record adjusted EBITDA margin of 6.5% in the second quarter of 2026, a high point for operational efficiency that was overshadowed by a significant drag from financial expenses and a clear deceleration in same-store sales (SSS) growth. The strong operational result, driven by effective cost control and leverage, delivered an adjusted net income of R$74 million, a 22% increase year-over-year, but still fell short of some analyst expectations due to a higher-than-anticipated financial result. For investors, the second-quarter report presents a complex picture of a company with sharpening operational acumen facing macroeconomic headwinds that are eroding bottom-line conversion.

The mechanism behind the record margin lies in Pague Menos's (PGMN3) successful integration and rationalization of its operations, particularly through the digital channel. The company’s digital sales soared 40.6% year-over-year, surpassing R$1 billion for the first time and now accounting for 24.1% of gross revenue. This robust digital growth and the resultant dilution of selling and administrative expenses were key in boosting the adjusted EBITDA margin by 0.35 percentage points compared to the prior year period. This pivot toward a more integrated, cost-efficient model demonstrates a clear managerial success in building a more profitable retail core.

However, the strength in margin was countered by two significant headwinds: decelerating sales growth and rising financing costs. Same-store sales advanced 8% in the quarter, a healthy figure on its own, but a marked slowdown from the 13% SSS growth reported just a quarter earlier. While the company's gross revenue was solid at R$4.3 billion, this deceleration signals a tougher operating environment and reflects the challenge of a high comparable base from previous periods. More critically, the net income conversion was limited by higher-than-expected financial expenses, a common challenge for companies in Brazil due to elevated interest rates, which directly hits the bottom line and limits the upside from the strong operational performance. The stock, a component of the Brazil Small-Cap ETF (EWZS), which is down 0.98% today, received a largely neutral reaction from analysts, balancing the consistent operational improvement against the persistent financial challenges.

Looking forward, the investment focus shifts to the balance between internal efficiencies and external financial pressures. Investors should monitor the company's continued progress in capturing Extrafarma synergies and the impact of the new Paraíba distribution center, which is anticipated to begin positively impacting margins in the third quarter of 2026. Crucially, the market will also be watching for any relief in the high-interest-rate environment that would temper the financial expenses drag, while tracking the next data point—the Q3 2026 earnings release scheduled for November 4, 2026—for confirmation on whether same-store sales growth stabilizes.